Clinically Extremely Vulnerable patients accessing new treatments in Guernsey:
Patients should contact their GP if they think they meet the criteria below and wish to access the new medications (antivirals or “neutralising monoclonal antibodies” -nMABs) for Covid. These drugs have been shown to reduce the risk of hospitalisation, although detailed assessment is necessary to determine which, if any, might be suitable for an individual. Some are tablets, but some require intravenous administration.
Who can qualify?
You must be in the “highest risk cohort” defined as (summary below or please see PDF download for full details):
- Down's syndrome
- sickle cell disease
- HIV or AIDS
- chronic kidney disease (CKD) stage 4 or 5
- certain types of cancer
- had certain types of chemotherapy in the last 12 months
- had radiotherapy in the last 6 months
- had an organ transplant
- a severe liver condition (such as cirrhosis)
- a rare condition affecting the brain or nerves (multiple sclerosis, motor neurone disease, Huntington's disease, or myasthenia gravis)
- certain autoimmune or inflammatory conditions (such as rheumatoid arthritis or inflammatory bowel disease)
- a condition or treatment that makes you more likely to get infections
A Doctor or Specialist will confirm if you are eligible for treatment.
- You must have a new diagnosis of COVID-19, within the last 5 days (PCR or Lateral Flow test)
- You must have symptoms of COVID-19,
- You must not be hospitalised or be needing new oxygen treatment for COVID-19.
I think I may qualify – what should I do?
- Contact your GP as soon as possible.
- Make clear that you think you may qualify for these new treatments.
What will happen next?
- Your GP will assess you, possibly with a face-to-face consultation.
- If your GP thinks you are suitable for one of these drugs, they will either prescribe the appropriate drug or refer you into secondary care, depending on the drug.
Where can I find further information?
It is extremely important to note that COVID-19 vaccination remains extremely important to help prevent severe disease and hospitalisation in this group – the availability of treatments does not change this.